ABSTRACT: With few notable exceptions, drug development for heart failure (HF) has become progressively more challenging, and there remain no definitively proven therapies for patients with acute HF or HF with preserved ejection fraction. Inspection of temporal trends suggests an increasing rate of disagreement between early-phase and phase III trial end points. Preliminary results from phase II HF trials are frequently promising, but increasingly followed by disappointing phase III results. Given this potential disconnect, it is reasonable to carefully re-evaluate the purpose, design, and execution of phase II HF trials, with particular attention directed toward the surrogate end points commonly used by these studies. In this review, we offer a critical reappraisal of the role of phase II HF trials and surrogate end points, highlighting challenges in their use and interpretation, lessons learned from past experiences, and specific strengths and weaknesses of various surrogate outcomes. We conclude by proposing a series of approaches that should be considered for the goal of optimizing the efficiency of HF drug development. This review is based on discussions between scientists, clinical trialists, industry and government sponsors, and regulators that took place at the Cardiovascular Clinical Trialists Forum in Washington, DC, on December 2, 2016.
O ver the past 30 years, outcomes for patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF) have dramatically improved with the development and implementation of multiple life-saving therapies. In the span of a decade, the field made relatively rapid advances with landmark trials generating foundational evidence for current guideline-directed medical therapy. [1] [2] [3] However, since those earlier times, the complexity and costs of drug development for HF have grown. Moreover, despite numerous specifically dedicated trials, patients with acute HF (AHF) and HF with preserved ejection fraction (HFpEF) remain without a single therapy definitively proven to improve outcomes.
In the context of efforts to improve HF drug development, available data from the past 2 decades suggest an increasing rate of disagreement between early-phase and definitive phase III trials. 4, 5 Findings from phase II trials are frequently interpreted as promising, only to be followed by disappointing phase III results. 6 Although reasons for a potential disconnect are complex and likely multifactorial, given the central nature of phase II trials and surrogate end points in the HF drug development paradigm, it is reasonable to re-evaluate their current and continued roles. In this review, we offer a critical reappraisal of the purpose of phase II trials and surrogate end points, highlighting challenges in their use and interpretation, lessons learned from past experiences, and specific strengths and weaknesses of various surrogate outcomes used in HFrEF, HFpEF, and AHF trials. We conclude by proposing a series of approaches that should be considered for optimizing the efficiency of HF drug development. This review is based on discussions between scientists, clinical trialists, industry and government sponsors, and regulators that took place at the Cardiovascular Clinical Trialists Forum in Washington, DC, on December 2, 2016. It is notable that the specific focus of this article is pharmacotherapy trials for HF, and considerations outlined here should be distinguished from discussions related to device-based therapy.
TRADITIONAL ROLES OF PHASE II AND SURROGATE END POINTS IN DRUG DEVELOPMENT
Phase II studies traditionally form the foundation for "go/no-go" decisions on large time-consuming and costly phase III trials intended to provide definitive data for potential regulatory approval and labeling. Phase II may also influence many of the phase III study design features, including the ultimate target population, dose, and safety monitoring. Phase IIb studies, in particular, are similar to phase III in that they are frequently assigned a single or small number of primary efficacy end points. However, unlike phase III, where HF trials are generally powered to evaluate mortality or hospitalization, primary efficacy end points for phase II trials are almost uniformly surrogate measures. 4 These end points facilitate limited sample size requirements and increase the feasibility of executing a smaller-budget trial over a shorter duration, while also allowing investigators to see the effect of the agent on measures believed to have strong correlation with clinical outcomes. 4 Thus, under the traditional approach, the importance of the specific surrogate efficacy end point choice in early-phase trials cannot be overstated. Although far from the only factor, the ultimate decision to abandon or continue development of an investigational agent, as well as the doses and outcomes to be tested, may be decided largely on its ability to meet these surrogate measures.
GENERAL LIMITATIONS OF SURROGATE END POINTS
Various types of measurements can be candidate surrogate end points, including laboratories, imaging studies, and physical examination findings. Moreover, although end points such as exercise tolerance and patientreported outcomes (eg, quality of life, dyspnea relief) are often termed "intermediate end points" since they measure their own independent clinical benefit, they are often viewed as potential surrogates for "hard" clinical outcomes such as death or hospitalization. 7 Overall, the use of surrogates in cardiovascular medicine has been fraught with challenges and requires a cautious approach. A study by Patel et al 5 suggests that, although rates of positive results in clinical end point trials have declined significantly over time, rates of positive surrogate and intermediate end point results remain consistently near 70% (Figure 1 ). Lessons lie in numerous historical examples of premature false confidence in surrogate markers. 8, 9 Specifically within the HF space, review of all phase II to phase IV HF trials from 2001 to 2012 shows that nearly 60% of all such trials used a surrogate or intermediate nonmortality primary end point. 4 These trials were more frequently positive than trials with end points including all-cause or cardiovascular mortality (74.4% versus 45.3%), consistent with a poor ability of phase II end points to predict late-phase results. 4 Although factors such as an increasing number of trials over time and potential temporal shifts in goals of phase II work may be acknowledged as possible contributors, the available trial-level data suggest a substantial rate of disagreement between phase II and phase III/IV end points. 4, 5 Accordingly, the bar for declaring a measure a reliable surrogate end point should be set high. Al- though virtually no surrogate is perfect, for a measure to serve as a reasonable and reliable marker for hard outcomes, several criteria are required, but not necessarily sufficient (Table 1) . 10, 11 Of these, perhaps the most difficult to achieve is for the correlation between therapeutically modulated levels of the marker and risk of outcome to be consistent across various classes of interventions and populations. 10 This latter point is particularly relevant to the use of surrogates in studies of novel therapies, where, by definition, the novelty of the intervention precludes prior validation of the biomarker in that setting. Indeed, investigational therapies are at risk of exerting deleterious effects that may neutralize or override any potential organ-specific benefits associated with change in the surrogate.
STATE OF THE ART
Although multiple measures have been used as HF surrogate end points, each carries significant limitations, and there remains no uniformly reliable surrogate efficacy end point for phase II drug trials in HF (Table 2) . We again distinguish the present discussion as directed toward development of pharmacological agents for HF and not necessarily applicable to medical devices, acknowledging that the role of surrogate end points in development and regulatory approval of devices may differ from drugs. 12 In the following sections, we consider the utility and challenges associated with frequently considered surrogate end points in early-phase HF trials of pharmacological agents.
SURROGATE END POINTS IN PHASE II DRUG TRIALS FOR HF Invasive Hemodynamics
Predating the contemporary HFrEF treatment paradigm centered on neurohormonal blockade, early treatment approaches focused on directly correcting hemodynamic abnormalities to reduce ventricular filling pressures and improve cardiac index. Based on encouraging hemodynamic data from early-phase studies, flosequinan was approved for use in chronic HF in Europe in September 1992 and in the United States shortly thereafter. [13] [14] [15] A subsequent phase III outcome study of flosequinan was terminated early because of increased mortality risk, leading to withdrawal of the drug from all markets. 16 Similarly, oral milrinone sparked enthusiasm as a treatment for severe refractory HF based on favorable hemodynamic effects, only to be later shown to increase mortality and other adverse events, and is no longer available. 17, 18 The HF literature contains multiple other examples highlighting that short-term hemodynamic effects with an investigational agent cannot reliably predict effects on mortality and hospitalization in HFrEF. 6 This assertion stands in potential contrast to long-term hemodynamic improvements, which may be less driven by sudden changes in preload, afterload, or contractility, but are presumably more likely to reflect favorable reverse remodeling or ventricular recovery. For example, β-blockers may sometimes cause acute hemodynamic worsening, but are cornerstone therapies for improving long-term outcomes.
Independent of the exact measures themselves, use of invasive hemodynamic surrogate end points in HF drug development has practical concerns. Since the publication of the ESCAPE trial (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness), which showed no benefit with use of a pulmonary artery catheter (PAC) in AHF, clinicians may be reluctant to insert a PAC, particularly for patients without hypotension. 19 Indeed, current HF guidelines discourage routine use of a PAC and recommend limiting use to patients with cardiogenic shock or mechanical ventilation. 20 Thus, while guidelines make routine use of invasive hemodynamic end points impracti- The measure must correlate with risk of the outcome in patients without a given medical intervention.
The measure must continue to correlate with risk of the outcome after modulation with a given therapy.
Therapeutically modulated levels of the measure must predict the net effect of the treatment on the clinical outcome.
The correlation between therapeutically modulated levels of the measure and risk of outcome must be consistent across various classes of interventions and population subsets. cal, difficulty rationalizing PAC use in trials is compounded by the common study requirement that patients be normotensive, or even relatively hypertensive. The phase II COMPOSE program offers an example. 21 Eligible patients were required to both have a "pre-existing requirement" for a PAC and a baseline systolic blood pressure >120 mm Hg. The study was terminated early, largely because of patient recruitment futility. Current guidelines discourage routine PAC placement. Common indication for PAC is cardiogenic shock, but most HF trials require patients to be normotensive or hypertensive, thus making trial enrollment challenging.
STATE OF THE ART

Change in NP level
Multiple examples of dissociation between treatment-related NP change and clinical outcomes (eg, levosimendan, aliskiren).
Comorbid atrial fibrillation may influence NP levels and hinder the ability of study therapy to decrease NP levels in HFrEF. The ability of a study therapy to meet an NP-defined end point may be influenced by the prevalence of atrial fibrillation in the overall trial population. Biological and analytic variability must be recognized in interpretation of serial troponin measurements (although may be less variability than NPs).
Cardiac imaging
Ejection fraction and ventricular volumes can change acutely with changes in loading conditions and contractility and may not necessarily represent intrinsic cardiac recovery.
Relationship between changes in diastolic function with therapy and subsequent clinical outcomes is poorly established in HFpEF.
2D echocardiography may present challenges with interreader variability, reproducibility, and image acquisition.
CMR and PET imaging are available only at select specialized centers and at relatively high cost.
Use of CMR limits enrollment of patients with implantable cardiac devices.
Functional capacity (eg, peak Vo 2, 6MWD)
Multiple examples of dissociation between change in exercise capacity and clinical outcomes (eg, flosequinan, ramipril, carvedilol).
Trial protocols subject to placebo effect whereby exercise capacity improves with familiarization with exercise protocol.
Potential for uneven intensification of background therapy between study arms during follow-up to maintain symptomatic stability. 6MWD may suffer from modest reproducibility and variability in clinician coaching/patient effort from 1 visit to the next and between study sites.
CPET testing only available at select centers, and burden of serial intensive exercise examinations on patients may be a challenge for trial recruitment.
Quality of life, dyspnea relief, and other patient-reported outcomes
Multiple examples of dissociation between change in quality of life and clinical outcomes (eg, flosequinan, spironolactone in HFpEF).
Potential for uneven intensification of background therapy between study arms during follow-up to maintain symptomatic stability.
Multiple grading instruments available and often no clear consensus on which is the gold standard. Examples exist where a therapy (eg, serelaxin) may improve a patient-reported outcome (eg, dyspnea relief) as measured by 1 grading instrument but not another.
Majority of patients with acute HF experience rapid (eg, within hours) and robust dyspnea relief with standard therapy. Dyspnea may no longer be severe by the time of patient enrollment, and it may be difficult for investigational therapies to show incremental improvement in dyspnea relief over standard therapy.
2D indicates 2-dimensional; 6MWD, 6-minute walk distance; CMR, cardiac magnetic resonance; CPET, cardiopulmonary exercise testing; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; NP, natriuretic peptide; PAC, pulmonary arterial catheter; PET, positron emission tomography; and Vo 2 , oxygen consumption.
is fraught with challenges. For example, the phase III ASTRONAUT trial (Aliskiren Trial on Acute Heart Failure Outcomes) found that the addition of aliskiren to standard HF therapy did not influence mortality or hospitalization end points, despite a statistically significant and sustained decrease in NT-proBNP (N-terminal pro-B-type natriuretic peptide) over 12-month follow-up ( Figure 2) . 22 A recent analysis across 16 chronic HF trials (excluding ASTRONAUT), most of which were HFrEF, identified similar dissociations between therapeutic effects on NPs and all-cause mortality, although a correlation with HF hospitalization was seen. 24 Nonetheless, correlations with HF hospitalization were driven largely by trials of reninangiotensin-aldosterone system inhibitors, and thus potentially less applicable to future drug development targeting other pathways. 24 In the context of multiple examples of concordance and discordance between change in NPs and mortality and hospitalization outcomes, such relationships may be most accurately described as therapy-specific. 25, 26 Although fewer data are available and rare examples of discordance exist, more consistent relationships may be seen when using treatment-related NP change as a surrogate for effects on patient-centered outcomes in chronic HFrEF, such as changes in symptoms, quality of life, or exercise capacity. 22, 27, 28 Atrial fibrillation may further complicate the effective use of a NP end point. Atrial fibrillation may be a mediator of elevated NP levels and HF patients with comorbid atrial fibrillation generally tend to have higher NP levels than those without. 29 Thus, it is plausible that an investigational HF therapy may have differing ability to lower NP level depending on the rhythm status of the patient, and that prevalence of atrial fibrillation in the study population could influence overall results. The ASTRONAUT investigators studied this hypothesis and found that the ability of aliskiren to lower NT-proBNP varied by baseline rhythm with incremental NP lowering through 12 month follow-up only among patients without baseline atrial fibrillation or flutter ( Figure 3 ). 
Heart Failure With Preserved Ejection Fraction
In addition to aforementioned issues, use of NP defined end points in HFpEF may carry additional challenges. Although NP levels carry prognostic significance comparable to HFrEF, absolute levels in HFpEF tend to be lower, with up to one-third of patients having normal levels despite significantly elevated filling pressures on invasive assessment. 31 In addition, although trial selection criteria based on elevated NP levels may facilitate recruitment of higherrisk patients, it may signal the inclusion of patients with advanced disease less likely to respond to study therapy. For example, in the I-PRESERVE trial (Irbesartan in Heart Failure with Preserved Ejection Fraction Trial) and TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist), patients with lower baseline NT-proBNP were more likely to respond to study therapy. 32, 33 Moreover, in the PARAMOUNT trial (Prospective Comparison of ARNI with ARB on Management of Heart Failure with Preserved Ejection Fraction), despite a sustained robust reduction in NT-proBNP during followup, LCZ696 did not improve patient-centered outcomes, including quality of life or a composite including New York Heart Association functional classification and patient global assessment. 34 These collective data suggest that conclusions regarding NP levels gained from patients with HFrEF need not apply to HFpEF. Further research is needed to understand the interaction between HFpEF and NP levels before the biomarker can be viewed as a reliable surrogate end point in HFpEF drug development.
Acute Heart Failure
Several AHF trials have demonstrated that rapid and robust lowering of NP is possible with multiple therapies, but that these short-term changes may not reliably track with improved downstream clinical or patient-reported outcomes (PROs). [35] [36] [37] For instance, in the SURVIVE trial (Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support), patients with AHF randomly assigned to levosimendan had greater decreases in NP level at 24 hours and 5 days than those receiving dobutamine, but similar scores on global and dyspnea assessments at 24 hours and similarly high rates of 180-day mortality. 35 
Change in NP Level: Application Within Clinical Trials
The biological and analytic variability of NP measurements must be recognized in their use as end points. For example, among patients with clinically stable HF, intraindividual variability of NT-proBNP levels 1 hour and 1 week apart may approach 7% and 21%, respectively. 38 Likewise, the analytic variability (ie, imprecision of the test) of the specific assay must be considered. To better distinguish altered patient status from inherent variability, prior work has described reference change values and suggested a change in NT-proBNP >50% to 60% as clinically relevant. 39, 40 Use of change in NT-proBNP as a surrogate end point is further complicated by the heterogeneous way in which the end point may be defined. These definitions may influence end point interpretation and highlight the need, at minimum, to ensure strict adherence to prespecified statistical methods and for consideration of sensitivity analyses using alternative approaches. 7 For example, recent studies have been variable in their decision to evaluate absolute change in NP as a continuous variable versus the proportion of patients achieving a specified reduction from baseline (eg, >30% relative reduction). 41, 42 In addition, some trials take a per-protocol or "completers" approach with the primary analysis, whereby only patients who are alive with valid baseline and follow-up NT-proBNP measurements are used in the primary analysis. 41 Benefits of such a strategy include the evaluation of complete data potentially most informative for dose finding. Nevertheless, this approach is subject to downstream imbalances in clinical or safety events between study groups, as it is conceivable that death or withdrawal of "sicker" patients in a particular study arm could bias the remaining population toward lower NTproBNP levels. Alternatively, other studies have followed the intention-to-treat principle, whereby the last observation carried forward or imputed values are inserted for patients not completing the study protocol. 34 Last, although the randomization process should support similar patient characteristics between study arms, the generally modest size of phase II trials increases risk of random baseline NP imbalances. Study groups randomly starting with higher baseline NP levels may be more likely to experience a greater subsequent decrease, independent of any differences in therapy between groups. For example, in both the ARTS-HF trial (Mineralocorticoid Receptor Antagonist Tolerability Study-Heart Failure) and the SOCRATES-REDUCED trial (Soluble Guanylate Cyclase Stimulator in Heart Failure with Reduced Ejection Fraction Study), patients in the control arm had substantially higher baseline NT-proBNP levels, potentially impacting the failure of both investigational agents to provide significant reduction relative to placebo and meet their respective primary end points.
41,42
Change in Troponin Level
Across the spectrum of HF, troponin levels are elevated in a significant proportion of patients in the absence of overt clinical ischemia. 43, 44 Although the exact mechanism of this myocardial injury is unclear, data support troponin elevation as a prognostic marker, and HF therapies that increase troponin (eg, inotropes) have generally led to worse clinical outcomes. [43] [44] [45] However, unlike elevation in NPs, it is biologically plausible that troponin elevation directly contributes to HF progression and poor outcomes, and thus may be a more suitable surrogate or therapeutic target. In addition, the biological variation profile of troponin relative to NPs may be better suited for serial measurement as a trial end point.
Specifically, troponin measures generally have less intraindividual variation than NPs, and reference change values suggest more modest changes are clinically relevant (ie, ≈30%). 40 Nonetheless, despite increased attention, HF therapies targeting troponin reduction have not reliably improved clinical outcomes, and future work is needed to clarify the potential utility of troponin as an end point in HFrEF, HFpEF, and AHF. Most recently, the neutral top line results from the RELAX-AHF2 trial (Relaxin in Acute Heart Failure-2; NCT01870778) showed no long-term mortality benefit of serelaxin therapy in AHF, despite favorable short-term effects on troponin and several other markers of organ injury in an earlier study. 36 In contrast, among patients with HFpEF enrolled in the PARAMOUNT trial, in comparison with valsartan, LCZ696 therapy resulted in further reduction in high-sensitivity troponin T and parallel improvements in NPs and left atrial size. 46 Of significant current interest, omecamtiv mecarbil has been consistently shown to produce low-level troponin elevation, and the definitive phase III outcome trial is ongoing (NCT02929329).
47,48
Cardiac Imaging
Heart Failure With Reduced Ejection Fraction
Imaging parameters have been regularly used as end points within early-phase HFrEF trials, with 2-dimensional echocardiography the most frequently used modality. Reverse remodeling has been a common focus, generally equated to an improvement in ejection fraction or ventricular volumes. 49 The rationale for these end points stems largely from a large meta-analysis across trials of patients with left ventricular dysfunction where short-term trial-level effects of a drug or device on ventricular remodeling were associated with longterm trial-level effects on mortality. 49 However, practical limitations to echocardiographic end points exist. First, neither ejection fraction nor ventricular dimensions directly measure intrinsic myocardial function, as both are highly influenced by preload and afterload conditions. Multiple examples exist where short-term changes in ejection fraction are discordant from effects on survival. 45 Second, echocardiographic measurements may demonstrate moderate interreader variability and suboptimal reproducibility, particularly in the setting of relatively modest improvements expected in most trials. 50 Third, despite frequent use of core laboratories intended to standardize interpretation, quality of local image acquisition within multicenter trials may vary, and issues with calibration of serial measurements may remain.
Heart Failure With Preserved Ejection Fraction
Aforementioned limitations notwithstanding, recent HFpEF trials have shown an increasing focus on echocardiographic end points, including diastolic function and left atrial volume. 34, 51 However, despite compelling biological plausibility, the utility of these measures in predicting patient outcomes is unclear. For example, in the ALDO-DHF trial (Aldosterone Receptor Blockade in Diastolic Heart Failure), randomization to spironolactone significantly improved the E/eʹ ratio in comparison with placebo, but did not improve HF symptoms or quality of life and slightly reduced 6-minute walk distance. 52 Likewise, despite secondary analyses of the TOPCAT trial suggesting clinical benefits with spironolactone among patients from North and South America, no corresponding reduction in left atrial volume was seen. 53 
Alternative Imaging Modalities Irrespective of Ejection Fraction
More recently, there has been increasing consideration of cardiac magnetic resonance (CMR) or positron emission tomography within trial design. 54, 55 In comparison with 2-dimensional echocardiography, CMR is a volumetric technique with high contrast and spatial resolution that favors improved accuracy and reproducibility for multiple measurements, including ejection fraction, volumes, and left ventricular mass. 56, 57 Because study power is dependent on effect size and inversely proportional to the variance of the measurement, use of CMR for end point assessment may facilitate a reduction in sample size. 57, 58 In addition, CMR also allows the evaluation of myocardial constituents (eg, myocyte, interstitium, microcirculation), and the degree of tissue viability and scar, as well. Such detailed evaluation of the myocardium offers the potential of serial assessments to detect a specific therapeutic effect (eg, change in myocardial fibrosis in response to an antifibrotic agent). Likewise, molecular imaging with positron emission tomography could provide novel insight into drug dose and target receptor engagement, and the metabolic function of the heart. 59 Nonetheless, despite the promise of both CMR and positron emission tomography as novel assessments of cardiac structure and function, to date, their use in drug development programs has been markedly limited. Thus, their effective use in reliably predicting a therapeutic response on clinical outcomes is unclear. Current hurdles to widespread use include availability limited to select centers, higher costs, longer examination times, and use of implantable cardioverter-defibrillators and pacemakers (for CMR).
Functional Capacity
Functional capacity is an important intermediate end point frequently evaluated in early-phase HF trials. The most commonly used measures in routine practice and clinical research are the 6-minute walk distance and cardiopulmonary exercise testing (eg, peak oxygen consumption). Both measures have demonstrated a consistent ability to predict downstream survival in HFrEF and HFpEF, and thus engendered great interest as surrogate end points in drug development. [60] [61] [62] Most recently, the NEAT-HFpEF trial (Nitrate's Effect on Activity Tolerance in Heart Failure with Preserved Ejection Fraction) introduced a novel wearable accelerometer to measure daily patient activity level. 63 Although the utility of this novel measure in future HF programs remains to be seen, an ancillary study from NEAT-HFpEF failed to show significant correlations between therapeutically mediated changes in accelerometer units and changes in traditional functional assessments, including 6-minute walk distance. 64 Despite evidence of prognostic value, the use of serial exercise measurements as effective surrogates for mortality in clinical trials has been problematic, with multiple instances of HFrEF therapies with proven survival benefits offering little to no effect on exercise tolerance. 65, 66 Likewise, inotropes may increase mortality despite improving functional capacity. 67 Reasons for such discordance are unclear, but a variety of issues could potentially obscure efficacy signals, including placebo effect (with improved exercise capacity with increased familiarization with the exercise protocol), uneven patient dropout between study arms, and uneven intensification of background therapy to maintain symptomatic stability between exercise assessments. 68 Moreover, with 6-minute walk distance in particular, concerns exist over the fidelity and reproducibility of serial measurements, and the variation in clinician "coaching" and patient effort from 1 visit to the next and between trial sites. These issues may be less problematic with cardiopulmonary exercise testing where the respiratory equivalence ratio can objectively characterize patient effort and core laboratories can better standardize interpretation. Nonetheless, cardiopulmonary exercise testing may only be available at select centers, and the burden of serial intensive exercise examinations on patients may present a challenge for trial enrollment.
Dyspnea Relief and PROs
Although increasingly recognized as intermediate end points with their own important intrinsic value, PROs among patients with HF have been frequently viewed in the context of surrogates for traditional mortality and hospitalization outcomes. Among PROs, dyspnea is the most common primary reason for HF hospitalization and is a frequently studied outcome in AHF trials. In contrast with other surrogates, dyspnea end points have extended beyond early-phase trials to use as a primary end point in phase III AHF studies. [69] [70] [71] [72] Although no longer necessarily the case, dyspnea relief had historically been a regulatory approval end point, for which there was precedent. 69 Regardless, use of dyspnea as an effective end point in HF trials has been consistently challenging. There remains no consensus on how to best measure dyspnea, and multiple grading instruments are available and inconsistently used.
Indeed, by meeting only 1 of 2 coprimary end points, the RELAX-AHF trial (Relaxin in Acute Heart Failure) highlights how an investigational agent may improve dyspnea as measured by 1 scale, but not another. 72 Moreover, the URGENT dyspnea study (Ularitide Global Evaluation in Acute Decompensated Heart Failure) suggested that >75% of patients with AHF have rapid dyspnea improvement within 6 hours of presentation with standard therapy. 73 Thus, dyspnea is often not severe by the time of study enrollment, likely hindering the ability of an investigational agent to show incremental improvement. In light of these ascertainment challenges, data linking dyspnea relief to improved longer-term quality of life, mortality, and rehospitalization outcomes are inconsistent. 74 Collectively, these data support dyspnea relief as an important patient-centered outcome, but not as a reliable substitute for clinical events, such as mortality or HF hospitalization. Similar conclusions can be applied to other PROs, including those derived from quality-of-life scales. 65, 67, 75 
FUTURE DIRECTIONS
Given the challenges outlined, use of surrogate end points and phase II trials in HF drug development warrants reassessment. In an effort to maximize chances of successful therapeutic development and improve trial efficiency and costs, we propose the following strategies (Figure 4) . Although the effectiveness of these considerations requires prospective validation, we believe them to be practical and to potentially offer key advantages over current approaches.
Tailor Phase II to Key Drug-Specific Questions
Recognizing that there remains no fully reliable surrogate end point for clinical events, we believe the principal purpose of contemporary phase II HF trials should not be to predict phase III results. Likewise, it stands to reason that these studies should not be held to phase III standards, and thus not be simplistically determined positive or neutral/negative by virtue of effects on a primary end point. Rather, we propose that early-phase studies be designed with the intent to better understand the mechanism and biological impact of therapy, including confirmation of on-target effects/receptor engagement, dose finding, and pharmacokinetics/pharmacodynamics. The ongoing development program for omecamtiv mecarbil may serve as an illustrative example. In this case, a preclinical and phase I program identified a clear mechanism of action (ie, increasing the transition rate to the Recognizing that there are no reliable surrogate outcomes for phase III mortality and hospitalization end points, we propose that the central goal of phase II should not be to predict phase III results but to optimize phase III execution and to clarify the drug mechanism and drug-patient interaction. Adaptive trial design may allow for a more efficient drug development process and may more directly allow information gained from phase II to shape the phase III trial. HF indicates heart failure. strongly bound myosin-actin cross-bridge state) with a biologically plausible and physiological marker of drug response (ie, systolic ejection time). 76 Subsequent phase II studies further validated drug effect by confirming dose-dependent effects on systolic ejection time and characterizing pharmacokinetics. 47, 77 Indeed, the primary end point of the largest phase II study of omecamtiv mecarbil in chronic HF (COSMIC-HF [Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure]) was the plasma concentration of the agent at 12 weeks, and not a generic surrogate end point (eg, change in NT-proBNP level, functional status). 47 Rather, investigators linked plasma concentration of the drug to secondary study end points specific to the drug mechanism (ie, systolic ejection time). Although the clinical efficacy and safety of omecamtiv mecarbil remains to be definitively determined, a similar developmental approach centered on rigorously confirming biological mechanism and "on-target" cardiac effects may prove more informative than evaluating isolated effects on a generic HF surrogate.
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Clinical Composite End Points and Multidimensional End Point Assessment
Consistent with the above-mentioned use of phase II studies to define the biological impact of therapy, simultaneous evaluation of multiple end point domains may be considered. Under this approach, there would be understanding that limited power may make achievement of statistical significance of any particular end point difficult. 79 Rather, the premise would be that congruent signals of benefit on multiple measures, such as symptoms, functional status, biomarkers, quality of life, and clinical outcomes, may best represent the merits of continued study in phase III. Alternatively, instead of independent assessment of multiple end points, composite outcomes may be used. Assignment of weights (ie, ranking) to individual components of a composite has been proposed, such as with use of a hierarchical clinical composite end point based on symptomatic, functional status, or quality-of-life improvement in the absence a worsening HF event (such as death or HF hospitalization). 68 Similarly, biomarkers may be incorporated within a global rank composite, as used in the phase II FIGHT study (Functional Impact of GLP-1 for Heart Failure Treatment). 79, 80 Others have proposed an average Z score end point where components of the composite are unweighted. 81 Under this approach, the treatment effect on each component is converted to a Z score and Z scores across outcomes are averaged. 81, 82 Regardless, although a multidomain end point approach may offer greater insight on the biological impact of therapy in comparison with studies using single or small numbers of single-domain primary end points, limitations should be acknowledged. We note that a multidomain approach may still fail to predict phase III results, with positive results for serelaxin in the phase IIb Pre-RELAX-AHF study (Preliminary Study of Relaxin in Acute Heart Failure) coupled with neutral results in the phase III RELAX-AHF2 trial being a notable example. 83 Moreover, composite end point results (eg, a unitless global rank score) and the corresponding effect sizes can be difficult to interpret clinically and subject to heterogeneity of effect across component outcomes. For example, a short follow-up duration diminishes the contribution of important but rare events (eg, mortality and hospitalization) to a hierarchical composite end point and increases the likelihood that overall results are dominated by other components (eg, traditional surrogates such as changes in dyspnea or NT-proBNP). 84 To better interpret composite end point results, Brown and Ezekowitz 81 have supported the use of the probability index, a bounded measure between 0 and 1 with a value of 0.5 suggesting no difference. The probability index represents the probability of a randomly selected patient from the treatment arm having a response superior to a randomly selected patient from the control arm. 81 An advantage of the probability index is that it readily describes the treatment effect size for component end points and overall composites using a common measure (rather than a combination of hazard ratios, differences between means, etc), thus facilitating the assessment of heterogeneity and clinical significance. 81 Although decisions for subsequent phase III investigations based on a series of singular measures or a composite outcome may inherently retain some degree of subjectivity, use of the probability index and prespecified procedures for considering end point heterogeneity and clinically meaningful benefits may favor more effective use of the multidomain end point approach in phase II.
Merging Phase II and Phase III With Adaptive Trial Design
Although traditional trial design involves a fixed prespecified sample size and final efficacy assessment after all subjects have been enrolled, an adaptive strategy monitors accruing data at set time points and includes prespecified criteria for modifying design features as the study moves forward. Recognizing that phase II oftentimes offers questionable value and that only an adequate phase III trial can reliably prove efficacy and safety, drug development programs may consider streamlining the process by specifying conditions whereby phase II studies transform directly into phase III. A study may start with a phase II design, but include interim assessments where early intimation of efficacy, harm, or futility on phase III end points are made using prespecified statistical boundaries ( Figure 5 ). 85 Although a trial could begin with a traditional phase II sample size and surrogate end point, interval signals for hard efficacy and safety end points would be tracked, and study leader-ship would reserve the prespecified right to convert toward phase III by increasing trial enrollment and changing the primary efficacy or safety end point. 85 Thus, the trial would have potential to increase study power, via preset criteria based on interim data, such that therapeutic efficacy and safety were definitively determined. Similarly, a phase II study might start with a primary intent of dose finding, and then continue directly to phase III with discontinuation of ineffective dosing arms.
Adaptive design may offer several advantages over traditional approaches. By starting with a conventional phase II sample size, study sponsors would still receive the initial clinical data they generally require before comfortably dedicating resources toward a large phase III trial. However, no patient data or study participants would be "wasted", and such a head start on phase III enrollment may be particularly valuable in this era of difficult and slow trial recruitment. Moreover, such a design may reduce costs to the sponsor by consolidating site training and start-up costs, requiring fewer overall patient participants, and decreasing time sponsors dedicate to investigational agents that eventually prove ineffective. An adaptive trial design does include limitations, such as data variability inherent to interim analyses, the requirement for carefully defined prespecified criteria to guide trial modification, the potential for bias because of possible alterations in investigator behavior following an adaptive change, and the possible inability of a small sponsor to provide upfront support for a large seamless phase II-phase III program. Nonetheless, this design strategy represents an attractive alternative that may be increasingly considered in HF. Effective examples of adaptive design have been seen in other areas of cardiovascular disease and in oncology. 85, 86 Proceed Directly to Phase III Without Phase II
In select circumstances, the most appropriate path for an investigational drug may be to skip phase II and proceed directly to phase III. Although such a course of action is unconventional, the recent landmark PARADIGM-HF trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) and the development of sacubitril/valsartan have highlighted this possibility. 87 Omapatrilat, a dual-acting angiotensin-converting enzyme inhibitor/ neprilysin inhibitor, was developed more than a decade ago and tested in the 5770-patient phase III OVERTURE trial (Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events), where it was superior to enalapril for the end point of cardiovascular death or hospitalization and in analyses including recurrent HF hospitalizations. 88 Despite these promising findings, the development of omipatrilat was terminated because of the excess risk of angioedema. Nonetheless, these collective data provided both the rationale for replacement of the angiotensin-converting enzyme inhibitor component with an angiotensin II receptor blocker to circumvent angioedema, and the foundational efficacy data supporting dual neprilysin and renin-angiotensinaldosterone system inhibition. A similar strategy of bypassing phase II may be reasonable if a drug compound shows an impressive HF efficacy signal in a large non-HF clinical outcome trial. For example, findings from the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose) among 7020 patients with type 2 diabetes mellitus found that treatment with Trial would start with a planned end. Interim analysis in the statistical promising zone would prompt sample size reestimation with addition of further patients and extension of the trial beyond the planned end, increasing chances of the trial finding a definitive result. Interim analysis in the favorable or unfavorable zone would not prompt the extension of the trial because the initial planned end would have reasonable probability of arriving at a definitive result. Interim analysis in the efficacy or futility zones would prompt the trial being stopped early before the planned end.
empagliflozin was associated with a 35% relative risk reduction for HF hospitalization, with findings consistent among subsets with and without HF at baseline. 89 Accordingly, the decision was made to initiate dedicated phase III trials among patients with established HF, irrespective of diabetes status (NCT03057977, NCT03057951).
Although conditions surrounding the development of sacubitril/valsartan and empagliflozin may be rare, both examples highlight situations where it is unclear if a traditional modestly sized phase II HF program could have offered information superior to the larger scale, but only closely related, clinical outcome data already available. Thus, these examples highlight a potential opportunity for bypassing phase II when ample large-scale randomized clinical data exist with (1) a very closely related drug in a HF population, or (2) the same drug in a closely related or overlapping trial population.
CONCLUSIONS
Over the past 2 decades, the frequency of positive phase III trial results with investigational HF drugs has declined, whereas the rates of positive phase II results using surrogate end points have remained high. Despite many cases of compelling biological plausibility, past experience strongly suggests that there remains no reliable and proven surrogate end point for phase III HF trial outcomes. Accordingly, a reappraisal of the design, execution, and purpose of phase II trials is warranted. It may be most appropriate to shift traditional thinking regarding phase II from intending to predict phase III results to a tailored approach specific to the study agent and focused on key questions relevant to the drug-patient interaction and drug mechanism. The overarching goal of such a strategy would be to provide investigators with information useful in optimizing the design and execution of a potential phase III program, rather than to predict the final result. Similarly, innovations in adaptive trial design have the potential to streamline the drug development process and decrease the time and cost required for definitive efficacy and safety data. All relevant stakeholders, including patients, healthcare providers, academicians, regulators, and industry sponsors, have strong incentives to optimize drug development in efforts to improve the outcomes of patients with HF. As part of this collective mission, added scrutiny toward the design, execution, and purpose of phase II trials and the use of surrogate end points carries the promise of significant potential benefit.
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